Prot #BIO-17-1142: Contribution of dopamine D3 receptor partial agonism of cariprazine to improve cognition and psychosis

Project: Research project

Project Details

Description

Cariprazine is a novel antipsychotic drug with a favorable side effect profile. Understanding the pharmacology of its actions on cognition and psychosis is important to differentiate it from other antipsychotic drugs. This revised proposal is focused on the role of the effects of cariprazine on the dopamine D3 receptor to enhance cognitive function and its antipsychotic action, using microdialysis in the ventral hippocampus and ventral striatum (nucleus accumbens).
StatusFinished
Effective start/end date4/15/174/15/18

Funding

  • Allergan Sales, LLC (Prot #BIO-17-1142)

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.